Gender Differences in Treatment Outcomes among Patients with Non-Small Cell Lung Cancer Given a Combination of Carboplatin and Paclitaxel

Publisher： Karger

E-ISSN： 1423-0232|75|3-4|169-174

ISSN： 0030-2414

Source： Oncology, Vol.75, Iss.3-4, 2008-10, pp. : 169-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel, Carboplatin and Gemcitabine Combination as Induction Chemotherapy for Stage IIIA N2 Bulky Non-Small Cell Lung Cancer

By  

Oncology, Vol. 69, Iss. 4, 2005-12 ,pp. : 295-300

Karger

Access to resources Recommend Favorite

Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non‐small‐cell lung cancer

By  

HISTOPATHOLOGY, Vol. 64, Iss. 3, 2014-02 ,pp. : 412-420

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dose Escalation Study of Paclitaxel in Combination with Fixed-Dose Irinotecan in Patients with Advanced Non-Small Cell Lung Cancer (JCOG 9807)

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 94-100

Karger

Access to resources Recommend Favorite

Three‐arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non–small cell lung cancer (NSCLC) patients who will not receive bevacizumab‐based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)

By  

CANCER, Vol. 121, Iss. 13, 2015-07 ,pp. : 2253-2261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-08 ,pp. : 683-688

Karger

Access to resources Recommend Favorite